STOCK TITAN

Taro to Release Full Year Results on May 23, 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Taro Pharmaceutical Industries Ltd. plans to release its financial results for the year ended March 31, 2023, after the close of market on Tuesday, May 23, 2023.
Positive
  • None.
Negative
  • None.

HAWTHORNE, N.Y.--(BUSINESS WIRE)-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the year ended March 31, 2023, after the close of market on Tuesday, May 23, 2023.

The release will be accessible on Taro’s website at www.taro.com.

About Taro
Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company’s website at www.taro.com.

William J. Coote

VP, Chief Financial Officer

(914) 345-9001

William.Coote@taro.com

Source: Taro Pharmaceutical Industries Ltd.

FAQ

When will Taro Pharmaceutical release its financial results for the year ended March 31, 2023?

Taro Pharmaceutical plans to release its financial results for the year ended March 31, 2023, after the close of market on Tuesday, May 23, 2023.

Where can I access the release?

The release will be accessible on Taro's website at www.taro.com.

Taro Pharmaceutical Industries Ltd.

NYSE:TARO

TARO Rankings

TARO Latest News

TARO Stock Data

1.59B
8.09M
78.48%
13.45%
0.11%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Haifa

About TARO

established in 1950, taro pharmaceutical industries ltd. is a research-based, international, specialty pharmaceutical company that develops, manufactures and markets prescription and over-the-counter pharmaceutical products. taro’s research programs and niche strategy have enabled the company to achieve gross margins that are among the highest in the specialty pharmaceutical sector.